Navigation Links
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
Date:12/3/2008

ers to fill positions, but are not bringing candidates in for interviews despite the recruiters having qualified individuals at the read. It may also be as simple as wanting stability during the holiday season; as stressful as it can be, the stress of changing jobs is not something many people want to add on. “Many people are taking time off to be with loved ones, or just taking time out to recharge their batteries,” said Michele Hopps with MedZilla.com, the Internet’s leading job board for pharmaceuticals and health care. “As 2008 starts to wind down, it’s a great time to update your resume or think about enrolling in some continuing education classes.”

About MedZilla.com:
Established in mid-1994, MedZilla is the original web site to serve career and hiring needs for professionals and employers in biotechnology, pharmaceuticals, medicine, science and healthcare. The MedZilla jobs database contains about 7,500 open positions. The resume database currently contains over 285,000 resumes with 16,800 less than three months old. These resources have been characterized as the largest, most comprehensive databases of their kind on the web in the industries served.

Medzilla® is a Registered Trademark owned by Medzilla Inc. Copyright ©2008, MedZilla, Inc. Permission is granted to reproduce and distribute this text in its entirety, and if electronically, with a link to the URL www.medzilla.com. For permission to quote from or reproduce any portion of this message, please contact Michele Hopps, Director of Marketing and Development, MedZilla, Inc. Email: mgroutage(at)medzilla.com.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1690844.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health
2. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
3. New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ
4. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
5. Juvaris BioTherapeutics Announces Six Scientific Presentations at Infectious Diseases Society of America (IDSA) Meeting October 6, 2007
6. Mylan to Host Investor Day on October 3, 2007
7. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
8. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
9. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
10. Biodel Inc. to Present at BIO InvestorForum 2007 Conference on October 11, 2007
11. Biodel Inc. to Present at Natixis Bleichroeder Hidden Gems Conference on October 8, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health
Other Biology Technology:The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 2The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 3The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 4The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 5The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 2Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 3Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 4Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 5Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 6Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 7Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system 8The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 2The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 3The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 4The development of a melanocortin MC4 receptor binding assay using the LEADseeker Multimodality Imaging System 5